Phaseline

Targets › DRD1

DRD1 (Dopamine receptor D1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 3; Neurology, Psychiatry; next expected readout Jan 2027.

G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P21728)

Open in Phaseline: the race on DRD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Emalex BiosciencesEcopipam
Dopamine D1 receptor antagonist
DRD1Phase 3Tourette SyndromeFeb 2028
Serina TherapeuticsSER-252 (PEOZ-apomorphine)
Dopamine receptor agonist (D1-like and D2-like dopamine receptors)
DRD1, DRD2, DRD3, DRD4, DRD5Phase 1PARKINSON DISEASE (Disorder)Jan 2027

Conditions

PARKINSON DISEASE (Disorder) (1) Tourette Syndrome (1)

Modalities

small molecule (2)

Companies

Serina Therapeutics (1) Emalex Biosciences (1)

Related targets

DRD2 (1) DRD3 (1) DRD4 (1) DRD5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.